Positron emission tomography imaging in neurological disorders (Q37980609)

26 August 2017

title

Positron emission tomography imaging in neurological disorders (English)

1 reference

positron emission tomography

26 August 2017

main subject

1 reference

1

Marios Politis

1 reference

26 August 2017

2

Paola Piccini

1 reference

26 August 2017

publication date

1 September 2012

1 reference

26 August 2017

1 reference

26 August 2017

volume

259

1 reference

26 August 2017

issue

9

1 reference

26 August 2017

page(s)

1769-1780

1 reference

Biomedical applications of cyclotrons and review of commercially available models

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

Positron emission tomography provides molecular imaging of biological processes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

Improved detection of focal cerebral blood flow changes using three-dimensional positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

Endogenous dopamine release after pharmacological challenges in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

Cognitive deficits and striato-frontal dopamine release in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

Dopamine release during sequential finger movements in health and Parkinson's disease: a PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

Consensus nomenclature for in vivo imaging of reversibly binding radioligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

Simplified reference tissue model for PET receptor studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

Parametric imaging of ligand-receptor binding in PET using a simplified reference region model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

Dopamine visualized in the basal ganglia of living man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

The relation of putamen and caudate nucleus 18F-Dopa uptake to motor and cognitive performances in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

Ageing and Parkinson's disease: substantia nigra regional selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

A follow-up study on 6-[18F]fluoro-L-dopa uptake in early Parkinson's disease shows nonlinear progression in the putamen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

Longitudinal progression of sporadic Parkinson's disease: a multi-tracer positron emission tomography study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

Visualizing vesicular dopamine dynamics in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

Positron emission tomographic imaging of the dopamine transporter with 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

[11C]RTI-32 PET studies of the dopamine transporter in early dopa-naive Parkinson's disease: implications for the symptomatic threshold

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

Evidence of dopamine dysfunction in the hypothalamus of patients with Parkinson's disease: an in vivo 11C-raclopride PET study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

Differential diagnosis of Parkinson's disease, multiple system atrophy, and Steele-Richardson-Olszewski syndrome: discriminant analysis of striatal 18F-dopa PET data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

Parkinson's disease symptoms: the patient's perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

Serotonin and Parkinson's disease: On movement, mood, and madness

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

Staging of serotonergic dysfunction in Parkinson's disease: an in vivo 11C-DASB PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

Depressive symptoms in PD correlate with higher 5-HTT binding in raphe and limbic structures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

Serotonergic mediated body mass index changes in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

Cue-induced striatal dopamine release in Parkinson's disease-associated impulsive-compulsive behaviours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

Cell therapy in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

Optimizing functional imaging protocols for assessing the outcome of fetal cell transplantation in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

Serotonergic neurons mediate dyskinesia side effects in Parkinson's patients with neural transplants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

Graft-induced dyskinesias in Parkinson's disease: High striatal serotonin/dopamine transporter ratio.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

Dyskinesias after neural transplantation in Parkinson's disease: what do we know and what is next?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

[11C]raclopride-PET studies of the Huntington's disease rate of progression: relevance of the trinucleotide repeat length

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

Huntington's disease progression. PET and clinical observations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

The relationship between striatal dopamine receptor binding and cognitive performance in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

Cortical dopamine dysfunction in symptomatic and premanifest Huntington's disease gene carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

Microglial activation correlates with severity in Huntington disease: a clinical and PET study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

Microglial activation in presymptomatic Huntington's disease gene carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

Hypothalamic involvement in Huntington's disease: an in vivo PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

Microglial activation in regions related to cognitive function predicts disease onset in Huntington's disease: a multimodal imaging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

Cortical control of movement in Huntington's disease. A PET activation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

Positron emission tomography after fetal transplantation in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

Striatal neural grafting improves cortical metabolism in Huntington's disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

Positron emission tomography imaging in multiple sclerosis-current status and future applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

PET visualization of microglia in multiple sclerosis patients using [11C]PK11195

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

Microglial imaging with positron emission tomography and atrophy measurements with magnetic resonance imaging in multiple sclerosis: a correlative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

Increased PK11195 PET binding in the cortex of patients with MS correlates with disability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

Relationship between corpus callosum atrophy and cerebral metabolic asymmetries in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

Functional Basis of Memory Impairment in Multiple Sclerosis: A [18F]FDG PET Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

Reduced glucose metabolism in the frontal cortex and basal ganglia of multiple sclerosis patients with fatigue: a 18F-fluorodeoxyglucose positron emission tomography study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

A longitudinal study of cerebral glucose metabolism, MRI, and disability in patients with MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

Clinical significance of reduced cerebral metabolism in multiple sclerosis: a combined PET and MRI study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

Imaging central nervous system myelin by positron emission tomography in multiple sclerosis using [methyl-¹¹C]-2-(4'-methylaminophenyl)- 6-hydroxybenzothiazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

The magnitude of dementia occurrence in the world

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

Early detection of Alzheimer's disease using neuroimaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

Amyloid load and cerebral atrophy in Alzheimer's disease: an 11C-PIB positron emission tomography study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

PET imaging of amyloid deposition in patients with mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

Clinical severity of Alzheimer's disease is associated with PIB uptake in PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

[11C]PIB binding in Parkinson's disease dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

In vivo amyloid imaging with PET in frontotemporal dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

Whole-body biodistribution and radiation dosimetry of 18F-GE067: a radioligand for in vivo brain amyloid imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

In-vivo measurement of activated microglia in dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

Microglial activation and amyloid deposition in mild cognitive impairment: a PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

Carbon 11-labeled Pittsburgh Compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

A Two-Compartment Description and Kinetic Procedure for Measuring Regional Cerebral [11C]Nomifensine Uptake Using Positron Emission Tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6428-3

Emission computed tomography

21 January 2018

1 reference

12 December 2020

[11C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease

1 reference

12 December 2020

PET imaging of neocortical monoaminergic terminals in Parkinson's disease

1 reference

12 December 2020

Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET.

1 reference

12 December 2020

Striatal kinetics of [11C]-( )-nomifensine and 6-[18F]fluoro-L-dopa in Parkinson's disease measured with positron emission tomography.

1 reference

12 December 2020

Delayed recovery of movement-related cortical function in Parkinson's disease after striatal dopaminergic grafts

1 reference

12 December 2020

Correction of head movement on PET studies: comparison of methods.

1 reference

12 December 2020

Metabolic network abnormalities in early Huntington's disease: an [(18)F]FDG PET study.

1 reference

12 December 2020

Increased density of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson's disease: a PET study with [11C]raclopride

1 reference

12 December 2020

In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease

1 reference

12 December 2020

Performance evaluation of a whole-body PET scanner using the NEMA protocol. National Electrical Manufacturers Association

1 reference

12 December 2020

PET studies on the early and differential diagnosis of Parkinson's disease.

1 reference

12 December 2020

Benzodiazepine receptor binding in Huntington's disease: [11C]flumazenil uptake measured using positron emission tomography

1 reference

12 December 2020

Physical characteristics of the ECAT EXACT3D positron tomograph

1 reference

12 December 2020

NEMA NU 2-2001 performance measurements of an LYSO-based PET/CT system in 2D and 3D acquisition modes.

1 reference

12 December 2020

Neuroimaging in dementia

1 reference

12 December 2020

The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity

1 reference

12 December 2020

10.1007/S00415-012-6428-3

Identifiers

DOI

1 reference

26 August 2017

1 reference